Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa Richards

Showing results (71-80 of 79) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 79 results.
Cell Metabolism|November 4, 2020
A Universal Gut-Microbiome-Derived Signature Predicts CirrhosisTae Gyu Oh, Susy M Kim, Cyrielle Caussy, et al.
Alimentary Pharmacology & Therapeutics|January 13, 2026
Clinical Trial: Semaglutide Versus Placebo in NIT-Assessed MASH-A Multicenter Randomised Placebo-Controlled Trial (SAMARA)Veeral Ajmera, Raj Vuppalanchi, Mandana Khalili, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 7, 2017
Association Between Obesity and Discordance in Fibrosis Stage Determination by Magnetic Resonance vs Transient Elastography in Patients With Nonalcoholic Liver DiseaseCyrielle Caussy, Jun Chen, Mosab H Alquiraish, et al.
Hepatology (Baltimore, Md.)|December 9, 2014
Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)Rohit Loomba, Claude B Sirlin, Brandon Ang, et al.
The Journal of Clinical Investigation|June 20, 2017
Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosisCyrielle Caussy, Meera Soni, Jeffrey Cui, et al.
The Journal of Clinical Investigation|November 1, 2022
Risk of advanced fibrosis in first-degree relatives of patients with nonalcoholic fatty liver diseaseNobuharu Tamaki, Noora Ahlholm, Panu K Luukkonen, et al.
Advances in Therapy|August 24, 2023
Ramipril for the Treatment of COVID-19: RAMIC, a Randomized, Double-Blind, Placebo-Controlled Clinical TrialDaniel Q Huang, Veeral Ajmera, Christian Tomaszewski, et al.
Hepatology (Baltimore, Md.)|October 18, 2024
Disparities in screening and risk stratification for Hispanic adults with metabolic dysfunction-associated steatotic liver diseaseMonica A Tincopa, Luis Antonio Díaz, Daniel Q Huang, et al.
Alimentary Pharmacology & Therapeutics|April 22, 2026
Global Longitudinal Assessment of MASLD Using Magnetic Resonance Elastography (GOLDMINE): A Multi-Center, International Prospective Cohort Study of Imaging Biomarkers in MASLD Clinical OutcomesSuzanne Sharpton, Luis Antonio Díaz, Kay Pepin, et al.
Pageof 8

Showing results (71-80 of 79) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
Cell Metabolism|November 4, 2020
A Universal Gut-Microbiome-Derived Signature Predicts CirrhosisTae Gyu Oh, Susy M Kim, Cyrielle Caussy, et al.
Alimentary Pharmacology & Therapeutics|January 13, 2026
Clinical Trial: Semaglutide Versus Placebo in NIT-Assessed MASH-A Multicenter Randomised Placebo-Controlled Trial (SAMARA)Veeral Ajmera, Raj Vuppalanchi, Mandana Khalili, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 7, 2017
Association Between Obesity and Discordance in Fibrosis Stage Determination by Magnetic Resonance vs Transient Elastography in Patients With Nonalcoholic Liver DiseaseCyrielle Caussy, Jun Chen, Mosab H Alquiraish, et al.
Hepatology (Baltimore, Md.)|December 9, 2014
Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)Rohit Loomba, Claude B Sirlin, Brandon Ang, et al.
The Journal of Clinical Investigation|June 20, 2017
Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosisCyrielle Caussy, Meera Soni, Jeffrey Cui, et al.
The Journal of Clinical Investigation|November 1, 2022
Risk of advanced fibrosis in first-degree relatives of patients with nonalcoholic fatty liver diseaseNobuharu Tamaki, Noora Ahlholm, Panu K Luukkonen, et al.
Advances in Therapy|August 24, 2023
Ramipril for the Treatment of COVID-19: RAMIC, a Randomized, Double-Blind, Placebo-Controlled Clinical TrialDaniel Q Huang, Veeral Ajmera, Christian Tomaszewski, et al.
Hepatology (Baltimore, Md.)|October 18, 2024
Disparities in screening and risk stratification for Hispanic adults with metabolic dysfunction-associated steatotic liver diseaseMonica A Tincopa, Luis Antonio Díaz, Daniel Q Huang, et al.
Alimentary Pharmacology & Therapeutics|April 22, 2026
Global Longitudinal Assessment of MASLD Using Magnetic Resonance Elastography (GOLDMINE): A Multi-Center, International Prospective Cohort Study of Imaging Biomarkers in MASLD Clinical OutcomesSuzanne Sharpton, Luis Antonio Díaz, Kay Pepin, et al.
Pageof 8